Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Truist Securities Maintains Hold on Sensata Technologies, Lowers Price Target to $43

Truist Securities analyst William Stein maintains Sensata Technologies (NYSE:ST) with a Hold and lowers the price target from $46 to $43.
byBenzinga Newsdesk
July 27, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

Truist Securities analyst William Stein maintains Sensata Technologies (NYSE:ST) with a Hold and lowers the price target from $46 to $43.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

AIM ImmunoTech Announces Publication Of Data From Roswell Park Comprehensive Cancer Center Phase 1 Study Evaluating Ampligen As A Component Of A Chemokine-Modulating Regimen In Metastatic Triple-Negative Breast Cancer

By Benzinga Newsdesk
November 14, 11:06 AM
AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today announced the publication of results from the Phase 1 study at Roswell Park Comprehensive Cancer Center in patients with metastatic triple-negative

AIM